Environmentalist warns against Mosaic’s EPA approved project to build a road with radioactive waste material. BY Alexis Jones Polk County. UPDATED 10:35 AM ET Apr. 16, ...

OAKLAND, Calif.--(BUSINESS WIRE)--Solar Mosaic (the "Company" or "Mosaic"), a fintech platform for U.S. residential solar and energy-efficient home improvements, today announced the Company filed ...

A 1,600-year-old Byzantine mosaic from a Christian monastery in Israel, featuring 55 medallions with hunting scenes and mythological characters, was recently put on public display.

DelveInsight’s, “Hunter Syndrome Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hunter Syndrome pipeline landscape.

The FDA has accepted for Priority Review the BLA for RGX-121 for the treatment of mucopolysaccharidosis II, also known as Hunter syndrome.

Hunter syndrome is a rare genetic disease that affects over 2,000 individuals worldwide, primarily males, and leads to physical, cognitive, and behavioral symptoms.

Mosaic Down Syndrome is a genetic condition in which a person is born with an extra copy of chromosome 21 in some cells, affecting less than 1% of those with Down syndrome.

Hunter syndrome is rare and the trial is small, so there are no pre-defined standards for the safety endpoints to be compared against, Denali said. Related.

GC Biopharma announced on the 5th that the Ministry of Food and Drug Safety has designated the treatment for severe Hunter syndrome, 'Hunterase ICV (intracerebroventricular),' as an orphan drug.

Hunter syndrome results from the absence of an enzyme needed to break down cellular waste. Without it, waste builds up in the body, causing progressive damage to various systems.

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now found a commercialization partner for both the U.S. and Asian markets.. That ...

DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, tividenofusp alfa (DNL310), for the treatment of individuals with Hunter syndrome (MPS II).